Text Version
Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities
PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby
Related Resources
Order Documents
NLM
Gateway
TOXNET
Consumer
Health
Clinical Alerts
ClinicalTrials.gov
PubMed
Central
Privacy Policy
|
 |
-
Fluoxetine treatment of children
and adults with autistic disorder and mental
retardation.
Cook EH Jr, Rowlett R, Jaselskis C,
Leventhal BL.
University of Chicago, IL.
An open trial
of pharmacological treatment with fluoxetine, ranging from 20 mg every
other day to 80 mg per day, led to a significant improvement in Clinical
Global Impressions ratings of Clinical Severity in 15 of 23 subjects
with autistic disorder and 10 of 16 subjects with mental retardation.
Six of 23 patients with autistic disorder and 3 of 16 patients with
mental retardation had side effects which significantly interfered with
function, consisting predominantly of restlessness, hyperactivity,
agitation, decreased appetite, or insomnia. Double-blind studies of the
efficacy of pharmacological agents that potently inhibit 5-HT uptake in
the treatment of mental retardation coexisting with Axis I psychiatric
disorders (especially obsessive-compulsive disorder) and autistic
disorder are warranted.
Publication Types:
PMID: 1644739 [PubMed - indexed for
MEDLINE]
|